CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 242 enrolled
Drug / intervention
stannous fluoride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02832375
NCT02832375Phase 3Completed

A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity

GlaxoSmithKline·interventional·Posted Jul 14, 2016·Updated May 25, 2017

In Brief

A Phase 3 clinical trial evaluating stannous fluoride and sodium monofluorophosphate for Dentin Sensitivity. Completed, enrolled 242 participants across 1 site.

Detailed Summary

This single center, comparative design study will be used to investigate the efficacy of an experimental stannous fluoride containing dentifrice in relieving dentinal hypersensitivity (DH) after short term use compared with a standard fluoride dentifrice.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 14, 2016
Enrollment StartMar 1, 2016
Primary CompletionMay 1, 2016
Study CompletionMay 12, 2016
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 10.0 years ago

Interventions

stannous fluoridedrug

0.454% w/w stannous fluoride containing 1100ppm of fluoride

sodium monofluorophosphatedrug

0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride